JP2013535423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013535423A5 JP2013535423A5 JP2013518741A JP2013518741A JP2013535423A5 JP 2013535423 A5 JP2013535423 A5 JP 2013535423A5 JP 2013518741 A JP2013518741 A JP 2013518741A JP 2013518741 A JP2013518741 A JP 2013518741A JP 2013535423 A5 JP2013535423 A5 JP 2013535423A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- triazolo
- trifluoromethoxy
- pyridin
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims description 254
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 229
- 125000001072 heteroaryl group Chemical group 0.000 claims description 213
- 125000003545 alkoxy group Chemical group 0.000 claims description 210
- 125000000217 alkyl group Chemical group 0.000 claims description 203
- 125000000623 heterocyclic group Chemical group 0.000 claims description 202
- 125000001424 substituent group Chemical group 0.000 claims description 191
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 175
- 125000000304 alkynyl group Chemical group 0.000 claims description 103
- 125000003342 alkenyl group Chemical group 0.000 claims description 102
- 125000001475 halogen functional group Chemical group 0.000 claims description 94
- -1 —CF 3 Chemical group 0.000 claims description 93
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 86
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims description 70
- 239000001257 hydrogen Substances 0.000 claims description 70
- 150000002431 hydrogen Chemical class 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 52
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 20
- 229910052805 deuterium Inorganic materials 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 20
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 16
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 6
- SOPXTTHIOLOJNS-UHFFFAOYSA-N 2-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 SOPXTTHIOLOJNS-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- GKECDORWWXXNRY-UHFFFAOYSA-N 2h-pyridin-3-one Chemical compound O=C1CN=CC=C1 GKECDORWWXXNRY-UHFFFAOYSA-N 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- WVCRMSJBMLAUEK-UHFFFAOYSA-N 2-(1,2,4-oxadiazol-3-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC3=NOC=N3)N=C2C=C1 WVCRMSJBMLAUEK-UHFFFAOYSA-N 0.000 claims description 2
- LJSSRJKRLOGJFW-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3SC4=CC=CC=C4N=3)N=C2C=C1 LJSSRJKRLOGJFW-UHFFFAOYSA-N 0.000 claims description 2
- YWZABFQZZGSQEQ-UHFFFAOYSA-N 2-(1,3-oxazol-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3OC=CN=3)N=C2C=C1 YWZABFQZZGSQEQ-UHFFFAOYSA-N 0.000 claims description 2
- XOBKXZRZGDWUJA-UHFFFAOYSA-N 2-(2,2,2-trifluoroethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1N2C(=O)N(CC(F)(F)F)N=C2C=CC=1C1=CC=C(OC(F)(F)F)C=C1 XOBKXZRZGDWUJA-UHFFFAOYSA-N 0.000 claims description 2
- OVXHQIODPLLPGS-UHFFFAOYSA-N 2-(2-hydroxy-3-phenoxypropyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1CC(O)COC1=CC=CC=C1 OVXHQIODPLLPGS-UHFFFAOYSA-N 0.000 claims description 2
- QFDHIAJTTBECEF-UHFFFAOYSA-N 2-(2-imidazo[1,2-a]pyrazin-8-yloxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C4=NC=CN4C=CN=3)N=C2C=C1 QFDHIAJTTBECEF-UHFFFAOYSA-N 0.000 claims description 2
- WJWGCBXJYLKGEI-UHFFFAOYSA-N 2-(2-isoquinolin-1-yloxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C4=CC=CC=C4C=CN=3)N=C2C=C1 WJWGCBXJYLKGEI-UHFFFAOYSA-N 0.000 claims description 2
- JPLBWJUVLUAHER-UHFFFAOYSA-N 2-(2-pyrazin-2-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3N=CC=NC=3)N=C2C=C1 JPLBWJUVLUAHER-UHFFFAOYSA-N 0.000 claims description 2
- VQMSMAKRFVGWKP-UHFFFAOYSA-N 2-(2-pyrazol-1-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCN3N=CC=C3)N=C2C=C1 VQMSMAKRFVGWKP-UHFFFAOYSA-N 0.000 claims description 2
- FGLZQEQLYKFHCZ-UHFFFAOYSA-N 2-(2-pyridazin-3-yloxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=NC=CC=3)N=C2C=C1 FGLZQEQLYKFHCZ-UHFFFAOYSA-N 0.000 claims description 2
- VECCJOMKYSSSIJ-UHFFFAOYSA-N 2-(2-pyridin-2-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3N=CC=CC=3)N=C2C=C1 VECCJOMKYSSSIJ-UHFFFAOYSA-N 0.000 claims description 2
- KPSXKNBCIVEAPH-UHFFFAOYSA-N 2-(2-pyridin-2-yloxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=CC=CC=3)N=C2C=C1 KPSXKNBCIVEAPH-UHFFFAOYSA-N 0.000 claims description 2
- BULIWKSBFXZAGF-UHFFFAOYSA-N 2-(2-pyridin-2-ylpropyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1C=CC=NC=1C(C)CN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 BULIWKSBFXZAGF-UHFFFAOYSA-N 0.000 claims description 2
- NJSCGQIPYJCGEK-UHFFFAOYSA-N 2-(2-pyridin-3-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3C=NC=CC=3)N=C2C=C1 NJSCGQIPYJCGEK-UHFFFAOYSA-N 0.000 claims description 2
- HCIVEOQQCFYJPE-UHFFFAOYSA-N 2-(2-pyrimidin-2-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3N=CC=CN=3)N=C2C=C1 HCIVEOQQCFYJPE-UHFFFAOYSA-N 0.000 claims description 2
- BDNLOHSMZUXJNE-UHFFFAOYSA-N 2-(2-pyrimidin-2-yloxyethyl)-6-(4-trimethylsilylphenyl)-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC([Si](C)(C)C)=CC=C1C1=CN2C(=O)N(CCOC=3N=CC=CN=3)N=C2C=C1 BDNLOHSMZUXJNE-UHFFFAOYSA-N 0.000 claims description 2
- BCMKIAFOKMLLCY-UHFFFAOYSA-N 2-(2-pyrimidin-4-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3N=CN=CC=3)N=C2C=C1 BCMKIAFOKMLLCY-UHFFFAOYSA-N 0.000 claims description 2
- LVDLJZHEVASLAG-UHFFFAOYSA-N 2-(2-pyrrolo[1,2-a]pyrazin-1-yloxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C4=CC=CN4C=CN=3)N=C2C=C1 LVDLJZHEVASLAG-UHFFFAOYSA-N 0.000 claims description 2
- OSQKXFGNSNWFOT-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC3OC4=CC=CC=C4CC3)N=C2C=C1 OSQKXFGNSNWFOT-UHFFFAOYSA-N 0.000 claims description 2
- JPBBULQEKZVHQV-UHFFFAOYSA-N 2-(3-phenoxypropyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCCOC=3C=CC=CC=3)N=C2C=C1 JPBBULQEKZVHQV-UHFFFAOYSA-N 0.000 claims description 2
- SIASCGMZXFPZNB-UHFFFAOYSA-N 2-(3-phenylprop-2-enyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=CC=3C=CC=CC=3)N=C2C=C1 SIASCGMZXFPZNB-UHFFFAOYSA-N 0.000 claims description 2
- RIONBHYBBHCCBB-UHFFFAOYSA-N 2-(3-pyridazin-3-yloxypropyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCCOC=3N=NC=CC=3)N=C2C=C1 RIONBHYBBHCCBB-UHFFFAOYSA-N 0.000 claims description 2
- JOABKTNOERGASJ-UHFFFAOYSA-N 2-(pyridin-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=CC=CC=3)N=C2C=C1 JOABKTNOERGASJ-UHFFFAOYSA-N 0.000 claims description 2
- OUOIJRKIRMVJNR-UHFFFAOYSA-N 2-(quinolin-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C4C=CC=CC4=CC=3)N=C2C=C1 OUOIJRKIRMVJNR-UHFFFAOYSA-N 0.000 claims description 2
- MZBYMEWBOVJKJG-UHFFFAOYSA-N 2-[(1-methylpyrazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CN1C=CC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 MZBYMEWBOVJKJG-UHFFFAOYSA-N 0.000 claims description 2
- AVSQLPAJCOPVGM-UHFFFAOYSA-N 2-[(1-methylpyrazol-4-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=NN(C)C=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 AVSQLPAJCOPVGM-UHFFFAOYSA-N 0.000 claims description 2
- ULZDGJTZMAKGPD-UHFFFAOYSA-N 2-[(2-methyl-1,3-oxazol-5-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC=C1CN1C(=O)N2C=C(C=3C=CC(=CC=3)C(F)(F)F)C=CC2=N1 ULZDGJTZMAKGPD-UHFFFAOYSA-N 0.000 claims description 2
- YWPYCDLKADHMCQ-GOSISDBHSA-N 2-[(2r)-3-(2-chlorophenoxy)-2-methoxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C([C@H](OC)CN1C(N2C=C(C=CC2=N1)C=1C=CC(OC(F)(F)F)=CC=1)=O)OC1=CC=CC=C1Cl YWPYCDLKADHMCQ-GOSISDBHSA-N 0.000 claims description 2
- YFLRCGNFZGDKJZ-QGZVFWFLSA-N 2-[(2r)-3-methoxy-2-[3-(trifluoromethyl)pyridin-2-yl]oxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C([C@H](COC)OC=1C(=CC=CN=1)C(F)(F)F)N(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 YFLRCGNFZGDKJZ-QGZVFWFLSA-N 0.000 claims description 2
- YWPYCDLKADHMCQ-SFHVURJKSA-N 2-[(2s)-3-(2-chlorophenoxy)-2-methoxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C([C@@H](OC)CN1C(N2C=C(C=CC2=N1)C=1C=CC(OC(F)(F)F)=CC=1)=O)OC1=CC=CC=C1Cl YWPYCDLKADHMCQ-SFHVURJKSA-N 0.000 claims description 2
- YFLRCGNFZGDKJZ-KRWDZBQOSA-N 2-[(2s)-3-methoxy-2-[3-(trifluoromethyl)pyridin-2-yl]oxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C([C@@H](COC)OC=1C(=CC=CN=1)C(F)(F)F)N(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 YFLRCGNFZGDKJZ-KRWDZBQOSA-N 0.000 claims description 2
- HVBIGQNMFRGYHK-UHFFFAOYSA-N 2-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=O)=N1 HVBIGQNMFRGYHK-UHFFFAOYSA-N 0.000 claims description 2
- NGXPLUHGOPEZPQ-UHFFFAOYSA-N 2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(4-trimethylsilylphenyl)-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)[Si](C)(C)C)=O)=N1 NGXPLUHGOPEZPQ-UHFFFAOYSA-N 0.000 claims description 2
- DCUSGGLEJVNADI-UHFFFAOYSA-N 2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[2-methyl-4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C(=CC(OC(F)(F)F)=CC=2)C)=O)=N1 DCUSGGLEJVNADI-UHFFFAOYSA-N 0.000 claims description 2
- PYCKDNAEOSDPSW-UHFFFAOYSA-N 2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(2,2,2-trifluoroethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OCC(F)(F)F)=CC=2)=O)=N1 PYCKDNAEOSDPSW-UHFFFAOYSA-N 0.000 claims description 2
- CIUYUJJQZDDGTM-UHFFFAOYSA-N 2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 CIUYUJJQZDDGTM-UHFFFAOYSA-N 0.000 claims description 2
- LVIVCBYJGVUQAJ-UHFFFAOYSA-N 2-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NON=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 LVIVCBYJGVUQAJ-UHFFFAOYSA-N 0.000 claims description 2
- WKKLMCJUZVSRLP-UHFFFAOYSA-N 2-[(4-methyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=COC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 WKKLMCJUZVSRLP-UHFFFAOYSA-N 0.000 claims description 2
- RPOMDDHFVCHVKW-UHFFFAOYSA-N 2-[(4-methyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=COC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=O)=N1 RPOMDDHFVCHVKW-UHFFFAOYSA-N 0.000 claims description 2
- CRLVACGUSHLQEQ-UHFFFAOYSA-N 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(ON=3)C3CC3)N=C2C=C1 CRLVACGUSHLQEQ-UHFFFAOYSA-N 0.000 claims description 2
- RRAJQAYXEXKFHG-UHFFFAOYSA-N 2-[(5-cyclopropyl-2-methylpyrazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CN1N=C(C2CC2)C=C1CN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 RRAJQAYXEXKFHG-UHFFFAOYSA-N 0.000 claims description 2
- NGBGOTULLHICLU-UHFFFAOYSA-N 2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-(3-phenoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=C(OC=3C=CC=CC=3)C=CC=2)=O)=N1 NGBGOTULLHICLU-UHFFFAOYSA-N 0.000 claims description 2
- MGKQMRGQRNCSMN-UHFFFAOYSA-N 2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 MGKQMRGQRNCSMN-UHFFFAOYSA-N 0.000 claims description 2
- CPZBZRZORXDGGZ-UHFFFAOYSA-N 2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=O)=N1 CPZBZRZORXDGGZ-UHFFFAOYSA-N 0.000 claims description 2
- OYTKMZYFUNPNRK-UHFFFAOYSA-N 2-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NN=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 OYTKMZYFUNPNRK-UHFFFAOYSA-N 0.000 claims description 2
- XODNHLRRHIVGBX-UHFFFAOYSA-N 2-[(5-methyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=CN=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 XODNHLRRHIVGBX-UHFFFAOYSA-N 0.000 claims description 2
- JQWGPQKUWHYCJW-UHFFFAOYSA-N 2-[(5-methyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=CN=C1CN1C(=O)N2C=C(C=3C=CC(=CC=3)C(F)(F)F)C=CC2=N1 JQWGPQKUWHYCJW-UHFFFAOYSA-N 0.000 claims description 2
- JMCLXORBNBWOEO-UHFFFAOYSA-N 2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 JMCLXORBNBWOEO-UHFFFAOYSA-N 0.000 claims description 2
- AVBIQOMJIYFZHZ-UHFFFAOYSA-N 2-[2-(2,4-difluorophenyl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound FC1=CC(F)=CC=C1CCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 AVBIQOMJIYFZHZ-UHFFFAOYSA-N 0.000 claims description 2
- VONZHFWGMKSOPA-UHFFFAOYSA-N 2-[2-(2,6-difluorophenyl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound FC1=CC=CC(F)=C1CCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 VONZHFWGMKSOPA-UHFFFAOYSA-N 0.000 claims description 2
- MABLDYZQBQZFDM-UHFFFAOYSA-N 2-[2-(2,6-dimethylphenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=CC=CC(C)=C1OCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 MABLDYZQBQZFDM-UHFFFAOYSA-N 0.000 claims description 2
- LROYJVODHXKYIJ-UHFFFAOYSA-N 2-[2-(2-chlorophenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C(=CC=CC=3)Cl)N=C2C=C1 LROYJVODHXKYIJ-UHFFFAOYSA-N 0.000 claims description 2
- ZTYBMLCVOOCLLE-UHFFFAOYSA-N 2-[2-(2-methoxyphenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC=CC=C1OCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 ZTYBMLCVOOCLLE-UHFFFAOYSA-N 0.000 claims description 2
- YZYPKNNBTUSEAI-UHFFFAOYSA-N 2-[2-(3-bromo-6-methoxypyridin-2-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC=C(Br)C(CCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 YZYPKNNBTUSEAI-UHFFFAOYSA-N 0.000 claims description 2
- LCYDBKHIAPRFCQ-UHFFFAOYSA-N 2-[2-(3-chlorophenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C=C(Cl)C=CC=3)N=C2C=C1 LCYDBKHIAPRFCQ-UHFFFAOYSA-N 0.000 claims description 2
- GRULTNVOGICNDD-UHFFFAOYSA-N 2-[2-(4,4-difluoropiperidin-1-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCN3CCC(F)(F)CC3)N=C2C=C1 GRULTNVOGICNDD-UHFFFAOYSA-N 0.000 claims description 2
- PYEUJAYDBPQGGK-UHFFFAOYSA-N 2-[2-(4,6-dimethylpyrimidin-2-yl)oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=CC(C)=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 PYEUJAYDBPQGGK-UHFFFAOYSA-N 0.000 claims description 2
- WIJCIFKHSGPZJO-UHFFFAOYSA-N 2-[2-(4-chlorophenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C=CC(Cl)=CC=3)N=C2C=C1 WIJCIFKHSGPZJO-UHFFFAOYSA-N 0.000 claims description 2
- UUEZDKYARYKPTK-UHFFFAOYSA-N 2-[2-(4-cyclopropylpyrimidin-2-yl)oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=C(C=CN=3)C3CC3)N=C2C=C1 UUEZDKYARYKPTK-UHFFFAOYSA-N 0.000 claims description 2
- OITOPVWUINLSRU-UHFFFAOYSA-N 2-[2-(4-fluorophenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1OCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 OITOPVWUINLSRU-UHFFFAOYSA-N 0.000 claims description 2
- WNCIIWSWCMIMQU-UHFFFAOYSA-N 2-[2-(4-methylphenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(C)=CC=C1OCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 WNCIIWSWCMIMQU-UHFFFAOYSA-N 0.000 claims description 2
- LMWZUQQEPACYHL-UHFFFAOYSA-N 2-[2-(4-methylsulfanylpyrimidin-2-yl)oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CSC1=CC=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 LMWZUQQEPACYHL-UHFFFAOYSA-N 0.000 claims description 2
- GUGCDVSZLLAGEO-UHFFFAOYSA-N 2-[2-(4-propan-2-yloxypyrimidin-2-yl)oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC(C)OC1=CC=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 GUGCDVSZLLAGEO-UHFFFAOYSA-N 0.000 claims description 2
- YXIXQPPNKVUIRT-UHFFFAOYSA-N 2-[2-(5-pyridin-3-ylpyridin-2-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3N=CC(=CC=3)C=3C=NC=CC=3)N=C2C=C1 YXIXQPPNKVUIRT-UHFFFAOYSA-N 0.000 claims description 2
- HGTRMKUOOYDDBC-JOCHJYFZSA-N 2-[2-[(3r)-3-(4-fluorophenoxy)pyrrolidin-1-yl]ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1O[C@H]1CN(CCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)CC1 HGTRMKUOOYDDBC-JOCHJYFZSA-N 0.000 claims description 2
- NNXWYNPCXFMLPG-UHFFFAOYSA-N 2-[2-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(COCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 NNXWYNPCXFMLPG-UHFFFAOYSA-N 0.000 claims description 2
- YBXKMLYTHQBHJQ-UHFFFAOYSA-N 2-[2-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenoxy]ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(C=2C(=CC=CC=2)OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 YBXKMLYTHQBHJQ-UHFFFAOYSA-N 0.000 claims description 2
- FIUJLHZTQNKDDW-UHFFFAOYSA-N 2-[2-[4-(2,2,2-trifluoroethoxy)pyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound FC(F)(F)COC1=CC=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 FIUJLHZTQNKDDW-UHFFFAOYSA-N 0.000 claims description 2
- DCAIURRVFNJFSR-UHFFFAOYSA-N 2-[2-[4-(2-hydroxyethoxy)pyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound OCCOC1=CC=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 DCAIURRVFNJFSR-UHFFFAOYSA-N 0.000 claims description 2
- OMPOZZVWEMYHAA-UHFFFAOYSA-N 2-[2-[4-(3,3-difluoroazetidin-1-yl)-5-fluoropyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C(N2CC(F)(F)C2)C(F)=CN=C1OCCN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 OMPOZZVWEMYHAA-UHFFFAOYSA-N 0.000 claims description 2
- FINVLTBKFNUEGB-UHFFFAOYSA-N 2-[2-[4-(4-chlorophenoxy)pyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=C(OC=4C=CC(Cl)=CC=4)C=CN=3)N=C2C=C1 FINVLTBKFNUEGB-UHFFFAOYSA-N 0.000 claims description 2
- WJAPRRQAVZDFOB-UHFFFAOYSA-N 2-[2-[4-(cyclopropylmethoxy)pyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=C(OCC4CC4)C=CN=3)N=C2C=C1 WJAPRRQAVZDFOB-UHFFFAOYSA-N 0.000 claims description 2
- IDVVEYCFEYNEGJ-UHFFFAOYSA-N 2-[2-[4-(dimethylamino)-5-fluoropyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=C(F)C(N(C)C)=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 IDVVEYCFEYNEGJ-UHFFFAOYSA-N 0.000 claims description 2
- RQALVPINBQGMCE-UHFFFAOYSA-N 2-[2-ethoxy-3-(4-fluoro-2-methoxyphenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1CC(OCC)COC1=CC=C(F)C=C1OC RQALVPINBQGMCE-UHFFFAOYSA-N 0.000 claims description 2
- ACSLOAIBGIAKBZ-UHFFFAOYSA-N 2-[2-ethoxy-3-[(2-methyl-1,3-benzothiazol-6-yl)oxy]propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1C=C2N=C(C)SC2=CC=1OCC(OCC)CN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 ACSLOAIBGIAKBZ-UHFFFAOYSA-N 0.000 claims description 2
- WVTQLJBWCSRDMW-UHFFFAOYSA-N 2-[2-hydroxy-3-(2-propan-2-yloxyphenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC(C)OC1=CC=CC=C1OCC(O)CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 WVTQLJBWCSRDMW-UHFFFAOYSA-N 0.000 claims description 2
- KWNBHJZWBRZVEO-UHFFFAOYSA-N 2-[2-hydroxy-3-[(2-methyl-1,3-benzothiazol-6-yl)oxy]propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=C2SC(C)=NC2=CC=C1OCC(O)CN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 KWNBHJZWBRZVEO-UHFFFAOYSA-N 0.000 claims description 2
- QRXWNGQHWYMZFJ-UHFFFAOYSA-N 2-[2-hydroxy-3-[3-oxo-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-2-yl]propoxy]benzonitrile Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1CC(O)COC1=CC=CC=C1C#N QRXWNGQHWYMZFJ-UHFFFAOYSA-N 0.000 claims description 2
- YLDVOFIKASMXON-UHFFFAOYSA-N 2-[3-(2-chlorophenoxy)-2-pyrimidin-2-yloxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC(COC=3C(=CC=CC=3)Cl)OC=3N=CC=CN=3)N=C2C=C1 YLDVOFIKASMXON-UHFFFAOYSA-N 0.000 claims description 2
- CKSVRMWEVBWXQA-UHFFFAOYSA-N 2-[3-(2-chlorophenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCCOC=3C(=CC=CC=3)Cl)N=C2C=C1 CKSVRMWEVBWXQA-UHFFFAOYSA-N 0.000 claims description 2
- JBKYHZVKJXFZMX-UHFFFAOYSA-N 2-[3-(2-fluorophenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound FC1=CC=CC=C1OCCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 JBKYHZVKJXFZMX-UHFFFAOYSA-N 0.000 claims description 2
- NMNPYFYTKLISDF-UHFFFAOYSA-N 2-[3-(2-methoxyphenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC=CC=C1OCCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 NMNPYFYTKLISDF-UHFFFAOYSA-N 0.000 claims description 2
- RSIBUGZZQAVBOM-UHFFFAOYSA-N 2-[3-(4-fluoro-2-methoxyphenoxy)-2-hydroxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC(F)=CC=C1OCC(O)CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 RSIBUGZZQAVBOM-UHFFFAOYSA-N 0.000 claims description 2
- JRDZTUMYLTXQDP-UHFFFAOYSA-N 2-[3-(4-fluoro-2-methoxyphenoxy)-2-methoxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1CC(OC)COC1=CC=C(F)C=C1OC JRDZTUMYLTXQDP-UHFFFAOYSA-N 0.000 claims description 2
- MNQWJFACOLCNSA-UHFFFAOYSA-N 2-[3-(4-fluoro-3-pyridin-3-ylphenyl)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=C(C=2C=NC=CC=2)C(F)=CC=C1CCCN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 MNQWJFACOLCNSA-UHFFFAOYSA-N 0.000 claims description 2
- KZGAUBIJVIHXTL-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1CCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 KZGAUBIJVIHXTL-UHFFFAOYSA-N 0.000 claims description 2
- BJGKPGUAWQJOTA-UHFFFAOYSA-N 2-[3-[3-oxo-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-2-yl]propoxy]benzonitrile Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCCOC=3C(=CC=CC=3)C#N)N=C2C=C1 BJGKPGUAWQJOTA-UHFFFAOYSA-N 0.000 claims description 2
- YYVTXNGSGPIDDN-UHFFFAOYSA-N 2-[3-[4-fluoro-3-(1,3-oxazol-2-yl)phenyl]propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=C(C=2OC=CN=2)C(F)=CC=C1CCCN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 YYVTXNGSGPIDDN-UHFFFAOYSA-N 0.000 claims description 2
- NELTZKZPWSUPCT-UHFFFAOYSA-N 2-[4-(4-ethoxypyrimidin-2-yl)oxyoxolan-3-yl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCOC1=CC=NC(OC2C(COC2)N2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 NELTZKZPWSUPCT-UHFFFAOYSA-N 0.000 claims description 2
- FDRCWVQKOJFPSP-UHFFFAOYSA-N 2-[[3-(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3ON=C(N=3)C=3C(=CC=CC=3Cl)Cl)N=C2C=C1 FDRCWVQKOJFPSP-UHFFFAOYSA-N 0.000 claims description 2
- CIUYUJJQZDDGTM-FIBGUPNXSA-N 2-[[3-(trideuteriomethyl)-1,2,4-oxadiazol-5-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound [2H]C([2H])([2H])C1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 CIUYUJJQZDDGTM-FIBGUPNXSA-N 0.000 claims description 2
- GECBYKRXMYAANX-UHFFFAOYSA-N 2-[[3-[[3-oxo-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-2-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]isoindole-1,3-dione Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(CN4C(C5=CC=CC=C5C4=O)=O)ON=3)N=C2C=C1 GECBYKRXMYAANX-UHFFFAOYSA-N 0.000 claims description 2
- QVMKWIQYYVXBPJ-UHFFFAOYSA-N 2-[[5-(chloromethyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(CCl)ON=3)N=C2C=C1 QVMKWIQYYVXBPJ-UHFFFAOYSA-N 0.000 claims description 2
- FZKREWRQMQAHGF-UHFFFAOYSA-N 2-[[5-(pyridin-2-yloxymethyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(COC=4N=CC=CC=4)ON=3)N=C2C=C1 FZKREWRQMQAHGF-UHFFFAOYSA-N 0.000 claims description 2
- CMHDTVBZJICYIX-UHFFFAOYSA-N 2-[[5-(pyrimidin-2-yloxymethyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(COC=4N=CC=CN=4)ON=3)N=C2C=C1 CMHDTVBZJICYIX-UHFFFAOYSA-N 0.000 claims description 2
- MJKBHISAVSPHNM-UHFFFAOYSA-N 2-[[5-[(2-ethoxyphenoxy)methyl]-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCOC1=CC=CC=C1OCC1=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=NO1 MJKBHISAVSPHNM-UHFFFAOYSA-N 0.000 claims description 2
- MNDYBFMGLXVTSQ-OAHLLOKOSA-N 2-[[5-[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)(C)OC[C@@H]1C1=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=NO1 MNDYBFMGLXVTSQ-OAHLLOKOSA-N 0.000 claims description 2
- MNDYBFMGLXVTSQ-HNNXBMFYSA-N 2-[[5-[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)(C)OC[C@H]1C1=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=NO1 MNDYBFMGLXVTSQ-HNNXBMFYSA-N 0.000 claims description 2
- IBWDGDOOVUPPRH-UHFFFAOYSA-N 2-methyl-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1N2C(=O)N(C)N=C2C=CC=1C1=CC=C(OC(F)(F)F)C=C1 IBWDGDOOVUPPRH-UHFFFAOYSA-N 0.000 claims description 2
- KETWVEPWCQNJBR-UHFFFAOYSA-N 2-methyl-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1N2C(=O)N(C)N=C2C=CC=1C1=CC=C(C(F)(F)F)C=C1 KETWVEPWCQNJBR-UHFFFAOYSA-N 0.000 claims description 2
- FIMNQKPVOLWTCX-UHFFFAOYSA-N 2-propan-2-yl-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1N2C(=O)N(C(C)C)N=C2C=CC=1C1=CC=C(OC(F)(F)F)C=C1 FIMNQKPVOLWTCX-UHFFFAOYSA-N 0.000 claims description 2
- OGLVRRGTKNGIOF-UHFFFAOYSA-N 2-pyridin-2-yl-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(C=3N=CC=CC=3)N=C2C=C1 OGLVRRGTKNGIOF-UHFFFAOYSA-N 0.000 claims description 2
- SSJXLMOUGLZTRT-UHFFFAOYSA-N 5-methoxy-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O=C1N2C(OC)=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=NN1CC1=NC(C)=NO1 SSJXLMOUGLZTRT-UHFFFAOYSA-N 0.000 claims description 2
- UTIFATCBAZTAGS-UHFFFAOYSA-N 5-methyl-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C(C)=C(C=4C=CC(OC(F)(F)F)=CC=4)C=CC3=N2)=O)=N1 UTIFATCBAZTAGS-UHFFFAOYSA-N 0.000 claims description 2
- BHJJYZZAPARKEZ-UHFFFAOYSA-N 5-methyl-6-[4-(trifluoromethoxy)phenyl]-2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC2=NNC(=O)N2C(C)=C1C1=CC=C(OC(F)(F)F)C=C1 BHJJYZZAPARKEZ-UHFFFAOYSA-N 0.000 claims description 2
- UMBHAMWTALDITM-UHFFFAOYSA-N 6-(3,4-dichlorophenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=C(Cl)C(Cl)=CC=2)=O)=N1 UMBHAMWTALDITM-UHFFFAOYSA-N 0.000 claims description 2
- AWBHWWVHNCWVBA-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=C(F)C(F)=CC=2)=O)=N1 AWBHWWVHNCWVBA-UHFFFAOYSA-N 0.000 claims description 2
- XHQYGWNZSTUTKL-UHFFFAOYSA-N 6-(3,5-difluoro-4-phenoxyphenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=C(F)C(OC=3C=CC=CC=3)=C(F)C=2)=O)=N1 XHQYGWNZSTUTKL-UHFFFAOYSA-N 0.000 claims description 2
- XVCKXUURUAEBQS-UHFFFAOYSA-N 6-(4-benzoylphenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=O)=N1 XVCKXUURUAEBQS-UHFFFAOYSA-N 0.000 claims description 2
- RPWUFPVCLXWYCF-UHFFFAOYSA-N 6-(4-chlorophenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(Cl)=CC=2)=O)=N1 RPWUFPVCLXWYCF-UHFFFAOYSA-N 0.000 claims description 2
- FAQRSQUWTHPXMK-UHFFFAOYSA-N 6-(4-chlorophenyl)-2-[(5-methyl-1,3-oxazol-2-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=CN=C1CN1C(=O)N2C=C(C=3C=CC(Cl)=CC=3)C=CC2=N1 FAQRSQUWTHPXMK-UHFFFAOYSA-N 0.000 claims description 2
- FJMLVEMQSDYXRP-UHFFFAOYSA-N 6-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=C(F)C(OC(F)(F)F)=CC=2)=O)=N1 FJMLVEMQSDYXRP-UHFFFAOYSA-N 0.000 claims description 2
- FVCUQQGWODVVEB-UHFFFAOYSA-N 6-[4-(4-chlorophenoxy)phenyl]-2-(2-pyrimidin-2-yloxyethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(Cl)=CC=C1OC1=CC=C(C2=CN3C(=O)N(CCOC=4N=CC=CN=4)N=C3C=C2)C=C1 FVCUQQGWODVVEB-UHFFFAOYSA-N 0.000 claims description 2
- WWFCNKUCFKPXRI-UHFFFAOYSA-N 6-[4-(4-chlorophenoxy)phenyl]-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC=3C=CC(Cl)=CC=3)=CC=2)=O)=N1 WWFCNKUCFKPXRI-UHFFFAOYSA-N 0.000 claims description 2
- SQZWPCQKGINHDT-UHFFFAOYSA-N 6-[4-(4-chlorophenoxy)phenyl]-2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC=3C=CC(Cl)=CC=3)=CC=2)=O)=N1 SQZWPCQKGINHDT-UHFFFAOYSA-N 0.000 claims description 2
- MEMWVMAOEBDEST-UHFFFAOYSA-N 6-[4-(4-fluorophenoxy)phenyl]-2-(2-pyrimidin-2-yloxyethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C2=CN3C(=O)N(CCOC=4N=CC=CN=4)N=C3C=C2)C=C1 MEMWVMAOEBDEST-UHFFFAOYSA-N 0.000 claims description 2
- CYVQWKYIMKBUQR-UHFFFAOYSA-N 6-[4-(4-fluorophenoxy)phenyl]-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=O)=N1 CYVQWKYIMKBUQR-UHFFFAOYSA-N 0.000 claims description 2
- DTAYFBAOZRTZFV-UHFFFAOYSA-N 6-[4-(4-fluorophenoxy)phenyl]-2-[[5-(hydroxymethyl)-1,2,4-oxadiazol-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(CO)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=O)=N1 DTAYFBAOZRTZFV-UHFFFAOYSA-N 0.000 claims description 2
- GBFWACWSCPFMSP-UHFFFAOYSA-N 6-[4-(4-fluorophenoxy)phenyl]-2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C2=CN3C(=O)NN=C3C=C2)C=C1 GBFWACWSCPFMSP-UHFFFAOYSA-N 0.000 claims description 2
- COFSCJGADUHZIB-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[2-[3-(trifluoromethyl)pyridin-2-yl]oxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C(=CC=CN=3)C(F)(F)F)N=C2C=C1 COFSCJGADUHZIB-UHFFFAOYSA-N 0.000 claims description 2
- KHJJLXOPUJOWGC-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[2-[5-(trifluoromethyl)pyrimidin-2-yl]oxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=CC(=CN=3)C(F)(F)F)N=C2C=C1 KHJJLXOPUJOWGC-UHFFFAOYSA-N 0.000 claims description 2
- RAKKAYAIZQOSQT-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[2-[6-(trifluoromethyl)pyridin-2-yl]oxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=C(C=CC=3)C(F)(F)F)N=C2C=C1 RAKKAYAIZQOSQT-UHFFFAOYSA-N 0.000 claims description 2
- IBYNBIZYZJFITL-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[[4-(trifluoromethoxy)phenyl]methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 IBYNBIZYZJFITL-UHFFFAOYSA-N 0.000 claims description 2
- VWQHRAHQPKHEDL-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[[5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(ON=3)C=3C=C(C=CC=3)C(F)(F)F)N=C2C=C1 VWQHRAHQPKHEDL-UHFFFAOYSA-N 0.000 claims description 2
- ILZUBCPZMJPETC-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[[6-(trifluoromethyl)pyridin-2-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(C=CC=3)C(F)(F)F)N=C2C=C1 ILZUBCPZMJPETC-UHFFFAOYSA-N 0.000 claims description 2
- WCKSPUOMUKLNAH-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)NN=C2C=C1 WCKSPUOMUKLNAH-UHFFFAOYSA-N 0.000 claims description 2
- FHOXTMMDQPXGEB-UHFFFAOYSA-N 6-[4-(trifluoromethyl)phenyl]-2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CN2C(=O)NN=C2C=C1 FHOXTMMDQPXGEB-UHFFFAOYSA-N 0.000 claims description 2
- FZHYZEQARYMTOK-UHFFFAOYSA-N 8-methyl-6-[4-(trifluoromethoxy)phenyl]-2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1N(C(NN=2)=O)C=2C(C)=CC=1C1=CC=C(OC(F)(F)F)C=C1 FZHYZEQARYMTOK-UHFFFAOYSA-N 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims description 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 206010022562 Intermittent claudication Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000007718 Stable Angina Diseases 0.000 claims description 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 2
- 125000005605 benzo group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- ZIEWSZYVEDTXGH-UHFFFAOYSA-N pyrimidine-4-carbonitrile Chemical compound N#CC1=CC=NC=N1 ZIEWSZYVEDTXGH-UHFFFAOYSA-N 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- BMELULDLBXUUMQ-UHFFFAOYSA-N 1-[(3,4-difluorophenyl)methyl]-2-oxo-n-[[3-(3-oxo-2h-[1,2,4]triazolo[4,3-a]pyridin-6-yl)phenyl]methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)C(C(=O)NCC=2C=C(C=CC=2)C2=CN3C(=O)NN=C3C=C2)=CC=C1 BMELULDLBXUUMQ-UHFFFAOYSA-N 0.000 claims 1
- HALIVDNAXHLUSG-UHFFFAOYSA-N 2-(2-phenoxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C=CC=CC=3)N=C2C=C1 HALIVDNAXHLUSG-UHFFFAOYSA-N 0.000 claims 1
- QSGFIGSRPYAVMI-UHFFFAOYSA-N 2-(3-pyrazin-2-yloxypropyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCCOC=3N=CC=NC=3)N=C2C=C1 QSGFIGSRPYAVMI-UHFFFAOYSA-N 0.000 claims 1
- ULQSVPQTXFDRBR-UHFFFAOYSA-N 2-(4-pyrimidin-2-yloxyoxolan-3-yl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(C3C(COC3)OC=3N=CC=CN=3)N=C2C=C1 ULQSVPQTXFDRBR-UHFFFAOYSA-N 0.000 claims 1
- QCEYKMMEGNHVKQ-UHFFFAOYSA-N 2-[(2-cyclopropyl-1,3-oxazol-4-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(OC=3)C3CC3)N=C2C=C1 QCEYKMMEGNHVKQ-UHFFFAOYSA-N 0.000 claims 1
- APBITVXQWUFSQW-UHFFFAOYSA-N 2-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(C)=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 APBITVXQWUFSQW-UHFFFAOYSA-N 0.000 claims 1
- BTIBQACUUFVHNX-UHFFFAOYSA-N 2-[(3-benzyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3ON=C(CC=4C=CC=CC=4)N=3)N=C2C=C1 BTIBQACUUFVHNX-UHFFFAOYSA-N 0.000 claims 1
- FVJXVFFYXMUTMD-UHFFFAOYSA-N 2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=O)=N1 FVJXVFFYXMUTMD-UHFFFAOYSA-N 0.000 claims 1
- GVLLPSKBAGVQRD-UHFFFAOYSA-N 2-[(3-methyl-1,2-oxazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1N=C(C)C=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 GVLLPSKBAGVQRD-UHFFFAOYSA-N 0.000 claims 1
- WSQMBQWQWAJCSH-UHFFFAOYSA-N 2-[(4-cyclopropyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3OC=C(N=3)C3CC3)N=C2C=C1 WSQMBQWQWAJCSH-UHFFFAOYSA-N 0.000 claims 1
- FBOKDLWWWSMXBH-UHFFFAOYSA-N 2-[(4-cyclopropyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3OC=C(N=3)C3CC3)N=C2C=C1 FBOKDLWWWSMXBH-UHFFFAOYSA-N 0.000 claims 1
- BSUJKFRZIQGHKG-UHFFFAOYSA-N 2-[(4-phenyl-1,2,5-oxadiazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3C(=NON=3)C=3C=CC=CC=3)N=C2C=C1 BSUJKFRZIQGHKG-UHFFFAOYSA-N 0.000 claims 1
- ZOVVXDVDXFAXEL-UHFFFAOYSA-N 2-[(5-cyclopropyl-1,3,4-oxadiazol-2-yl)methyl]-6-[4-(4-fluorophenoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C2=CN3C(=O)N(CC=4OC(=NN=4)C4CC4)N=C3C=C2)C=C1 ZOVVXDVDXFAXEL-UHFFFAOYSA-N 0.000 claims 1
- FLWDCZOHCTZLJQ-UHFFFAOYSA-N 2-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3SC(=NN=3)C3CC3)N=C2C=C1 FLWDCZOHCTZLJQ-UHFFFAOYSA-N 0.000 claims 1
- BKADYUJMCKIJDE-UHFFFAOYSA-N 2-[(5-cyclopropyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3OC(=CN=3)C3CC3)N=C2C=C1 BKADYUJMCKIJDE-UHFFFAOYSA-N 0.000 claims 1
- CRTDEOBLJALPST-UHFFFAOYSA-N 2-[(5-methyl-1,2-oxazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=CC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 CRTDEOBLJALPST-UHFFFAOYSA-N 0.000 claims 1
- GCWWAYFSWSKCCY-UHFFFAOYSA-N 2-[(5-pyridin-2-yl-1,2-oxazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC3=NOC(=C3)C=3N=CC=CC=3)N=C2C=C1 GCWWAYFSWSKCCY-UHFFFAOYSA-N 0.000 claims 1
- RAKGMCRBTMCOED-UHFFFAOYSA-N 2-[1-(3-ethyl-1,2,4-oxadiazol-5-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCC1=NOC(C(C)N2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 RAKGMCRBTMCOED-UHFFFAOYSA-N 0.000 claims 1
- CSOAIKTXKJYPAL-UHFFFAOYSA-N 2-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1C(C)C1=NC(C)=NO1 CSOAIKTXKJYPAL-UHFFFAOYSA-N 0.000 claims 1
- XGDHSJGDFPOONA-UHFFFAOYSA-N 2-[2-(1-methylbenzimidazol-2-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N=1C2=CC=CC=C2N(C)C=1CCN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 XGDHSJGDFPOONA-UHFFFAOYSA-N 0.000 claims 1
- MFCRZFOKCWGDLN-UHFFFAOYSA-N 2-[2-(3-cyclopropylpyridin-2-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3C(=CC=CN=3)C3CC3)N=C2C=C1 MFCRZFOKCWGDLN-UHFFFAOYSA-N 0.000 claims 1
- NJUWJIRXCMEKIJ-UHFFFAOYSA-N 2-[2-(3-methylpyrazol-1-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C(C)C=CN1CCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 NJUWJIRXCMEKIJ-UHFFFAOYSA-N 0.000 claims 1
- BIDPHMBOBGPSFW-UHFFFAOYSA-N 2-[2-(4-chloropyrazol-1-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCN3N=CC(Cl)=C3)N=C2C=C1 BIDPHMBOBGPSFW-UHFFFAOYSA-N 0.000 claims 1
- WTMKJIOBWCFNNX-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1CCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 WTMKJIOBWCFNNX-UHFFFAOYSA-N 0.000 claims 1
- HROAXNIKKKJMJR-UHFFFAOYSA-N 2-[2-(4-phenylimidazol-1-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCN3C=C(N=C3)C=3C=CC=CC=3)N=C2C=C1 HROAXNIKKKJMJR-UHFFFAOYSA-N 0.000 claims 1
- PBOLJUHFEBCLEW-UHFFFAOYSA-N 2-[2-(5-chloro-4-methoxypyrimidin-2-yl)oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=C(Cl)C(OC)=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 PBOLJUHFEBCLEW-UHFFFAOYSA-N 0.000 claims 1
- YQPKTLJATZYGSK-UHFFFAOYSA-N 2-[2-hydroxy-3-(2-phenylphenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1CC(O)COC1=CC=CC=C1C1=CC=CC=C1 YQPKTLJATZYGSK-UHFFFAOYSA-N 0.000 claims 1
- LOZNQJGOYFAIMZ-UHFFFAOYSA-N 2-[3-(4,5-dichloro-2-methoxyphenoxy)-2-hydroxypropyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC(Cl)=C(Cl)C=C1OCC(O)CN1C(=O)N2C=C(C=3C=CC(=CC=3)C(F)(F)F)C=CC2=N1 LOZNQJGOYFAIMZ-UHFFFAOYSA-N 0.000 claims 1
- HCGFFJNOBZZEFK-UHFFFAOYSA-N 2-[3-(4-chloropyridin-3-yl)prop-2-ynyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC#CC=3C(=CC=NC=3)Cl)N=C2C=C1 HCGFFJNOBZZEFK-UHFFFAOYSA-N 0.000 claims 1
- YEURUVYSYMOYEU-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound FC(OC1=CC=C(C=C1)N1N=C2N(C=CC=C2)C1=O)(F)F YEURUVYSYMOYEU-UHFFFAOYSA-N 0.000 claims 1
- IISQOFPCGIIYLN-UHFFFAOYSA-N 2-[[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3ON=C(N=3)C=3C(=CC=CC=3)Cl)N=C2C=C1 IISQOFPCGIIYLN-UHFFFAOYSA-N 0.000 claims 1
- UCOVZXULYPKXSE-UHFFFAOYSA-N 2-[[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(C=2C=C(CN3C(N4C=C(C=CC4=N3)C=3C=CC(OC(F)(F)F)=CC=3)=O)C=CC=2)=N1 UCOVZXULYPKXSE-UHFFFAOYSA-N 0.000 claims 1
- VLGOKQMHVAJDGL-UHFFFAOYSA-N 2-[[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COCC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 VLGOKQMHVAJDGL-UHFFFAOYSA-N 0.000 claims 1
- DXJAQZHODOOFHY-UHFFFAOYSA-N 2-[[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COCC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=O)=N1 DXJAQZHODOOFHY-UHFFFAOYSA-N 0.000 claims 1
- QCHBVKBITVXFML-UHFFFAOYSA-N 2-[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC=CC=C1C1=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=NO1 QCHBVKBITVXFML-UHFFFAOYSA-N 0.000 claims 1
- ARDUIERVYQWNFN-UHFFFAOYSA-N 2-[[5-(3-methylpyridin-2-yl)-1,2-oxazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=CC=CN=C1C1=CC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=NO1 ARDUIERVYQWNFN-UHFFFAOYSA-N 0.000 claims 1
- MYLLQEZLGWNREX-UHFFFAOYSA-N 2-[[5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C(F)F)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 MYLLQEZLGWNREX-UHFFFAOYSA-N 0.000 claims 1
- FXEVEXAZTVDNCC-UHFFFAOYSA-N 2-[[5-(methoxymethyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(COC)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 FXEVEXAZTVDNCC-UHFFFAOYSA-N 0.000 claims 1
- LWCNUTAQWBMTMY-UHFFFAOYSA-N 6-(4-chloro-3-fluorophenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=C(F)C(Cl)=CC=2)=O)=N1 LWCNUTAQWBMTMY-UHFFFAOYSA-N 0.000 claims 1
- FVWAVLHWMKAFBA-UHFFFAOYSA-N 6-[4-(4-fluorophenoxy)phenyl]-2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=O)=N1 FVWAVLHWMKAFBA-UHFFFAOYSA-N 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 88
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 20
- 125000002947 alkylene group Chemical group 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- WDRJNKMAZMEYOF-UHFFFAOYSA-N 4-(trifluoromethoxy)phenol Chemical compound OC1=CC=C(OC(F)(F)F)C=C1 WDRJNKMAZMEYOF-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- FSYNSILTXXDMQJ-UHFFFAOYSA-N 2-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC=CC=C1OCC(O)CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 FSYNSILTXXDMQJ-UHFFFAOYSA-N 0.000 description 1
- VOGMJXDGKJVSMN-UHFFFAOYSA-N 2-[3-(2-ethoxyphenoxy)-2-hydroxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCOC1=CC=CC=C1OCC(O)CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 VOGMJXDGKJVSMN-UHFFFAOYSA-N 0.000 description 1
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- 0 CC(C(*)=C(*)N12)=C(*)C1=NN(*)C2=O Chemical compound CC(C(*)=C(*)N12)=C(*)C1=NN(*)C2=O 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36105610P | 2010-07-02 | 2010-07-02 | |
| US61/361,056 | 2010-07-02 | ||
| PCT/US2011/042700 WO2012003392A1 (en) | 2010-07-02 | 2011-06-30 | Fused heterocyclic compounds as ion channel modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015225781A Division JP2016029107A (ja) | 2010-07-02 | 2015-11-18 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013535423A JP2013535423A (ja) | 2013-09-12 |
| JP2013535423A5 true JP2013535423A5 (enExample) | 2014-08-14 |
| JP5858586B2 JP5858586B2 (ja) | 2016-02-10 |
Family
ID=44338422
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518741A Expired - Fee Related JP5858586B2 (ja) | 2010-07-02 | 2011-06-30 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
| JP2015225781A Pending JP2016029107A (ja) | 2010-07-02 | 2015-11-18 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015225781A Pending JP2016029107A (ja) | 2010-07-02 | 2015-11-18 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8703759B2 (enExample) |
| EP (1) | EP2588197B1 (enExample) |
| JP (2) | JP5858586B2 (enExample) |
| KR (1) | KR101911560B1 (enExample) |
| CN (1) | CN103096977B (enExample) |
| AU (1) | AU2011272787B2 (enExample) |
| BR (1) | BR112012033402A2 (enExample) |
| CA (1) | CA2802288C (enExample) |
| EA (1) | EA026385B9 (enExample) |
| ES (1) | ES2529119T3 (enExample) |
| IL (1) | IL223724A (enExample) |
| MX (1) | MX2012015096A (enExample) |
| NZ (1) | NZ604478A (enExample) |
| PT (1) | PT2588197E (enExample) |
| TW (1) | TWI537266B (enExample) |
| WO (1) | WO2012003392A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725290B (zh) * | 2009-07-27 | 2016-03-09 | 吉利德科学股份有限公司 | 作为离子通道调节剂的稠合杂环化合物 |
| NZ604478A (en) * | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| BR112013028886A2 (pt) | 2011-05-10 | 2016-08-09 | Gilead Sciences Inc | compostos heterocíclicos fundidos como moduladores dde canal de sódio |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| US9266881B2 (en) * | 2011-11-14 | 2016-02-23 | Merck Sharp & Dohme Corp. | Triazolopyridinone PDE10 inhibitors |
| HK1201455A1 (en) | 2012-01-27 | 2015-09-04 | Gilead Sciences Inc | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| WO2014153037A1 (en) * | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Substituted triazolopyridines and methods of use thereof |
| DK3105226T3 (da) | 2014-02-13 | 2019-10-14 | Incyte Corp | Cyclopropylaminer som lsd1-inhibitorer |
| PT3105218T (pt) | 2014-02-13 | 2019-12-05 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9856256B2 (en) * | 2014-06-17 | 2018-01-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridino[1,2-A]pyrimidone analogue used as P13K inhibitor |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| EP3626720A1 (en) | 2015-04-03 | 2020-03-25 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| CN105001217A (zh) * | 2015-06-16 | 2015-10-28 | 浙江工业大学 | 一种[1,2,4]三唑[4,3-α]吡啶-3(2H)-酮衍生物的制备方法 |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| US20170081323A1 (en) | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease |
| PE20190377A1 (es) | 2016-04-22 | 2019-03-08 | Incyte Corp | Formulaciones de un inhibidor de lsd 1 |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| JP7190906B2 (ja) | 2017-01-24 | 2022-12-16 | 住友化学株式会社 | 縮合複素環化合物及びそれを含有する組成物 |
| WO2018148745A1 (en) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
| US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) * | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| WO2019043635A1 (en) | 2017-09-01 | 2019-03-07 | Richter Gedeon Nyrt. | COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE |
| EP3801535A4 (en) | 2018-05-30 | 2022-03-02 | Praxis Precision Medicines, Inc. | ION CHANNEL MODULATORS |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| GB202216960D0 (en) * | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4230705A (en) | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4244953A (en) | 1979-10-24 | 1981-01-13 | American Cyanamid Company | Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4812565A (en) | 1982-09-30 | 1989-03-14 | A. H. Robins Company, Incorporated | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4654343A (en) | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4746655A (en) | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE4010488A1 (de) | 1990-03-31 | 1991-10-02 | Hoechst Ag | Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten |
| CA2044564A1 (en) | 1990-06-28 | 1991-12-29 | Quirico Branca | Amino acid derivatives |
| CN1060467A (zh) | 1990-09-25 | 1992-04-22 | 武田药品工业株式会社 | 1，3-苯并嗪衍生物、其生产方法和用途 |
| JPH04209692A (ja) | 1990-12-03 | 1992-07-31 | Asahi Glass Co Ltd | フォトクロミック材料 |
| DE69209576T4 (de) | 1991-05-10 | 1997-01-30 | Takeda Chemical Industries Ltd | Pyridinderivate, deren Herstellung und Anwendung |
| US5939412A (en) | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| JP3497164B2 (ja) | 1991-06-28 | 2004-02-16 | スミスクライン・ビーチャム・コーポレイション | 二環式フィブリノーゲン拮抗薬 |
| US5674863A (en) | 1991-10-18 | 1997-10-07 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
| US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH06107647A (ja) | 1992-08-12 | 1994-04-19 | Takeda Chem Ind Ltd | １，３−ベンゾオキサジン誘導体の製造法 |
| US5442055A (en) | 1992-11-13 | 1995-08-15 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| US6011150A (en) | 1992-11-13 | 2000-01-04 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| GB9225860D0 (en) | 1992-12-11 | 1993-02-03 | Smithkline Beecham Plc | Novel treatment |
| GB9226302D0 (en) | 1992-12-17 | 1993-02-10 | Smithkline Beecham Plc | Pharmaceuticals |
| US5550229A (en) | 1993-06-23 | 1996-08-27 | Tanabe Seiyaku Co., Ltd. | Alkylation process for preparing azetidinone compound and starting compound therefor |
| DE19526173A1 (de) | 1995-07-18 | 1997-01-30 | Hoechst Ag | Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung |
| JPH09157262A (ja) | 1995-12-08 | 1997-06-17 | Tanabe Seiyaku Co Ltd | アゼチジノン誘導体及びその合成中間体の製法 |
| GB9619492D0 (en) | 1996-09-18 | 1996-10-30 | Smithkline Beecham Plc | Novel treatment |
| JP2001526643A (ja) | 1997-04-18 | 2001-12-18 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環 |
| JP3964053B2 (ja) | 1997-07-10 | 2007-08-22 | 三井化学株式会社 | 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法 |
| DE69802204T2 (de) | 1997-09-08 | 2002-04-18 | Unilever N.V., Rotterdam | Verfahren zur verbesserung der enzymeaktivität |
| WO1999041246A1 (en) | 1998-02-11 | 1999-08-19 | Du Pont Pharmaceuticals Company | Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors |
| IL137720A0 (en) | 1998-02-18 | 2001-10-31 | Neurosearch As | Compounds and their use as positive ampa receptor modulators |
| EP1123297A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| US6627651B1 (en) | 1999-05-07 | 2003-09-30 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| EP1210332B1 (en) | 1999-08-27 | 2006-05-31 | The Procter & Gamble Company | Bleach boosting components, compositions and laundry methods |
| JP2003508588A (ja) | 1999-08-27 | 2003-03-04 | ザ、プロクター、エンド、ギャンブル、カンパニー | 陽イオン系処方成分を使用する、色に対して安全な洗濯方法 |
| BR0013616B1 (pt) | 1999-08-27 | 2011-12-27 | composiÇço de alvejamento e composto catalisador orgÂnico de lavanderia. | |
| MXPA02002128A (es) | 1999-08-27 | 2002-09-02 | Procter & Gamble | Componentes para formulacion estable, composiciones y metodos para lavanderia que los emplean. |
| CA2381924A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Color safe laundry methods employing zwitterionic formulation components |
| WO2001016275A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Fast-acting formulation components, compositions and laundry methods employing same |
| JP2003508581A (ja) | 1999-08-27 | 2003-03-04 | ザ、プロクター、エンド、ギャンブル、カンパニー | 処方成分の制御された有効化法、それを使用する組成物および洗濯方法 |
| WO2001087883A1 (en) | 2000-05-15 | 2001-11-22 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| CA2417156A1 (en) | 2000-08-01 | 2003-01-23 | Ono Pharmaceutical Co., Ltd. | 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient |
| CA2419255A1 (en) | 2000-08-29 | 2002-03-07 | Ish Kumar Khanna | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| US6822664B2 (en) * | 2000-10-11 | 2004-11-23 | Microsoft Corporation | Browser navigation for devices with a limited input system |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| WO2002051441A1 (en) | 2000-12-26 | 2002-07-04 | Sankyo Company, Limited | Medicinal compositions containing diuretic and insulin resistance-improving agent |
| PL363959A1 (en) | 2001-03-09 | 2004-11-29 | Pfizer Products Inc. | Triazolopyridines as anti-inflammatory agents |
| US6998408B2 (en) | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2005089298A (ja) | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| JP2003277384A (ja) | 2002-03-26 | 2003-10-02 | Kyorin Pharmaceut Co Ltd | 縮合ニ環式ピリジン誘導体 |
| JP2003321461A (ja) | 2002-04-25 | 2003-11-11 | Kyorin Pharmaceut Co Ltd | 縮合ビフェニル誘導体 |
| WO2004014880A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
| PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
| JPWO2004026292A1 (ja) | 2002-09-20 | 2006-01-12 | 株式会社ツムラ | 鎮咳薬 |
| US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| GB0223730D0 (en) * | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
| AU2003285946A1 (en) | 2002-10-22 | 2004-05-13 | The Trustees Of The University Of Pennsylvania | Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases |
| CA2504735C (en) * | 2002-11-07 | 2009-06-23 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| CN100430386C (zh) * | 2002-11-07 | 2008-11-05 | 默克公司 | 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病 |
| BRPI0406736A (pt) | 2003-01-13 | 2005-12-20 | Cortex Pharma Inc | Método de tratar declìnico cognitivo devido à privação de sono e estresse |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| DE10317526A1 (de) | 2003-04-16 | 2004-11-04 | Degussa Ag | Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen |
| AU2004232939A1 (en) | 2003-04-17 | 2004-11-04 | Merck Sharp & Dohme Corp. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| US20060264496A1 (en) | 2003-04-25 | 2006-11-23 | H. Lundbeck A/S | Substituted indoline and indole derivatives |
| CA2530081A1 (en) | 2003-07-01 | 2005-01-13 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| AR045445A1 (es) | 2003-08-05 | 2005-10-26 | Vertex Pharma | Compuestos ihinibidores de canales ionicos regulados por voltaje |
| US20050239767A1 (en) | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
| JP2007514730A (ja) | 2003-12-18 | 2007-06-07 | ファイザー・プロダクツ・インク | ｐ３８ＭＡＰキナーゼ阻害剤による、動物における急性の炎症の治療方法 |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
| WO2006002470A1 (en) | 2004-06-30 | 2006-01-12 | Monash University | Chiral ligands for asymmetric catalysis |
| JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
| JP2007297283A (ja) | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
| WO2006020959A2 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| US7625888B2 (en) | 2004-08-23 | 2009-12-01 | Merck & Co., Inc. | Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| AU2005285083B2 (en) | 2004-09-13 | 2011-03-10 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirohydantoin CGRP receptor antagonists |
| WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| US7579348B2 (en) | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| AU2006247136C1 (en) | 2005-05-17 | 2020-01-16 | Bausch + Lomb Ireland Limited | Compositions and methods for treatment of eye disorders |
| TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| AU2006259294A1 (en) | 2005-06-17 | 2006-12-28 | Wyeth | Tricyclic compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists |
| US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| US7572808B2 (en) * | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
| WO2007004028A2 (en) | 2005-06-30 | 2007-01-11 | Ranbaxy Laboratories Limited | Processes for the preparation of penems and its intermediate |
| US8932641B2 (en) | 2005-08-26 | 2015-01-13 | Amnos Co., Ltd. | Dried amnion and method for drying treatment of amnion |
| JP2009508963A (ja) | 2005-09-21 | 2009-03-05 | インサイト・コーポレイション | アミド化合物および医薬組成物としてのその使用 |
| JP2009508966A (ja) | 2005-09-23 | 2009-03-05 | シェーリング コーポレイション | 治療薬としての縮合四環性ｍＧｌｕＲ１アンタゴニスト |
| WO2007047604A2 (en) | 2005-10-18 | 2007-04-26 | Elixir Pharmaceuticals, Inc. | Sirt1 inhibition |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| WO2007061677A2 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam aryl cgrp receptor antagonists |
| WO2007061696A2 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam bicyclic cgrp receptor antagonists |
| TW200734342A (en) | 2005-12-15 | 2007-09-16 | Astrazeneca Ab | New compounds for the treatment of cardiac arrhythmias |
| KR20080082618A (ko) | 2005-12-16 | 2008-09-11 | 알콘, 인코퍼레이티드 | Ａｌｋ5 조절제를 사용한 안압의 조절 |
| US8013073B2 (en) | 2005-12-30 | 2011-09-06 | Chevron Oronite Company Llc | Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds |
| WO2007113226A1 (en) | 2006-03-31 | 2007-10-11 | Novartis Ag | Organic compounds |
| WO2007146284A2 (en) | 2006-06-12 | 2007-12-21 | Vertex Pharmaceuticals Incorporated | Thienopyrimidines useful as modulators of ion channels |
| JP2009542673A (ja) | 2006-06-29 | 2009-12-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ヒスタミンｈ３−受容体関連障害の治療に有用なヒスタミンｈ３−受容体モジュレータ |
| JP5642963B2 (ja) | 2006-06-30 | 2014-12-17 | スネシス ファーマシューティカルズ，インコーポレイティド | ピリジノニルｐｄｋ１阻害剤 |
| WO2008007661A1 (en) | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Tricyclic heterocyclic compound and use thereof |
| US20100035756A1 (en) | 2006-07-12 | 2010-02-11 | Syngenta Limited | Triazolophyridine derivatives as herbicides |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US7790741B2 (en) | 2006-10-06 | 2010-09-07 | Abbott Laboratories | Imidazothiazoles and imidazoxazoles |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| JP5512274B2 (ja) | 2006-10-23 | 2014-06-04 | セファロン、インク． | ＡＬＫ阻害剤およびｃ−ＭＥＴ阻害剤としての２，４−ジアミノピリミジンの縮合二環式誘導体 |
| CA2667826C (en) | 2006-10-28 | 2013-10-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EP2128134A1 (en) | 2006-11-02 | 2009-12-02 | Shionogi&Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
| US20080153840A1 (en) | 2006-12-21 | 2008-06-26 | Luiz Belardinelli | Reduction of cardiovascular symptoms |
| US8076350B2 (en) | 2006-12-22 | 2011-12-13 | Abbott Laboratories | Spirocyclic azaadamantane derivatives and methods of use |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| US8247403B2 (en) | 2007-03-07 | 2012-08-21 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| WO2008144483A2 (en) | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| EP2170337A4 (en) | 2007-06-28 | 2013-12-18 | Abbvie Inc | NEW TRIAZOLOPYRIDAZINE |
| US20110263569A1 (en) | 2007-08-22 | 2011-10-27 | President And Fellows Of Harvard College | Ryanodine channel binders and uses thereof |
| AP2010005202A0 (en) | 2007-09-12 | 2010-04-30 | Wyeth Llc | Isoquinolinyl and isoindolinyl derivatives as histamines-3 antagonists |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| CA2704125A1 (en) | 2007-12-19 | 2009-07-09 | Genentech, Inc. | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| WO2009089027A1 (en) | 2008-01-09 | 2009-07-16 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health | Phosphodiesterase inhibitors |
| WO2009100380A1 (en) | 2008-02-06 | 2009-08-13 | Cv Therapeutics, Inc. | Use of ranolazine for treating pain |
| KR20100124262A (ko) * | 2008-02-13 | 2010-11-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 비시클로아민 유도체 |
| WO2009137462A2 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2009137499A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
| DE102008024182A1 (de) | 2008-05-19 | 2009-11-26 | Merck Patent Gmbh | Verbindungen für organische elektronische Vorrichtung |
| MX2010013399A (es) * | 2008-06-06 | 2010-12-21 | Abbott Lab | Nuevos compuestos de 1,2,4-oxadiazol y sus metodos de uso. |
| ES2472323T3 (es) | 2008-06-17 | 2014-06-30 | Astrazeneca Ab | Compuestos de piridina |
| CA2730377C (en) | 2008-07-11 | 2017-09-19 | Neumedics | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
| EP2314583B1 (en) | 2008-08-12 | 2015-02-25 | Nippon Soda Co., Ltd. | Nitrogenated heterocyclic derivative, and agricultural or horticultural bactericidal agent |
| WO2010022001A1 (en) | 2008-08-18 | 2010-02-25 | Im&T Research, Inc. | Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto |
| WO2010028173A2 (en) | 2008-09-04 | 2010-03-11 | Gilead Palo Alto, Inc. | Method of treating atrial fibrillation |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| US8389500B2 (en) | 2008-10-30 | 2013-03-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| EP2373653B1 (en) | 2008-12-05 | 2014-04-02 | F. Hoffmann-La Roche AG | Pyrrolopyrazinyl urea kinase inhibitors |
| NZ593937A (en) | 2008-12-08 | 2014-05-30 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
| BRPI0922180A2 (pt) | 2008-12-08 | 2015-12-29 | Sirtris Pharmaceuticals Inc | insoindolinona e análogos correlatos como moduladores de sirtuína |
| FR2943342B1 (fr) | 2009-03-20 | 2011-03-04 | Servier Lab | Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| KR20110131312A (ko) | 2009-03-27 | 2011-12-06 | 프레시디오 파마슈티칼스, 인코포레이티드 | 융합된 고리 ｃ형 간염 억제제 |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| CN102725290B (zh) | 2009-07-27 | 2016-03-09 | 吉利德科学股份有限公司 | 作为离子通道调节剂的稠合杂环化合物 |
| ES2444779T3 (es) | 2009-09-28 | 2014-02-26 | F. Hoffmann-La Roche Ag | Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer |
| WO2011075607A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| NZ604478A (en) * | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| WO2012019071A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
| WO2012019076A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| WO2012071509A2 (en) | 2010-11-24 | 2012-05-31 | Exelixis, Inc. | Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture |
| BR112013028886A2 (pt) | 2011-05-10 | 2016-08-09 | Gilead Sciences Inc | compostos heterocíclicos fundidos como moduladores dde canal de sódio |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| HK1201455A1 (en) | 2012-01-27 | 2015-09-04 | Gilead Sciences Inc | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
-
2011
- 2011-06-30 NZ NZ604478A patent/NZ604478A/en not_active IP Right Cessation
- 2011-06-30 AU AU2011272787A patent/AU2011272787B2/en not_active Ceased
- 2011-06-30 EA EA201291272A patent/EA026385B9/ru not_active IP Right Cessation
- 2011-06-30 BR BR112012033402A patent/BR112012033402A2/pt not_active Application Discontinuation
- 2011-06-30 KR KR1020137001153A patent/KR101911560B1/ko not_active Expired - Fee Related
- 2011-06-30 EP EP11732540.7A patent/EP2588197B1/en active Active
- 2011-06-30 PT PT117325407T patent/PT2588197E/pt unknown
- 2011-06-30 JP JP2013518741A patent/JP5858586B2/ja not_active Expired - Fee Related
- 2011-06-30 CN CN201180042654.5A patent/CN103096977B/zh not_active Expired - Fee Related
- 2011-06-30 US US13/174,587 patent/US8703759B2/en active Active
- 2011-06-30 WO PCT/US2011/042700 patent/WO2012003392A1/en not_active Ceased
- 2011-06-30 ES ES11732540.7T patent/ES2529119T3/es active Active
- 2011-06-30 CA CA2802288A patent/CA2802288C/en not_active Expired - Fee Related
- 2011-06-30 MX MX2012015096A patent/MX2012015096A/es active IP Right Grant
- 2011-07-01 TW TW100123352A patent/TWI537266B/zh not_active IP Right Cessation
-
2012
- 2012-12-18 IL IL223724A patent/IL223724A/en active IP Right Grant
-
2014
- 2014-03-17 US US14/217,011 patent/US9079901B2/en active Active
-
2015
- 2015-11-18 JP JP2015225781A patent/JP2016029107A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013535423A5 (enExample) | ||
| ES2642586T3 (es) | Compuestos heterocíclicos condensados como moduladores de canales iónicos | |
| JP6356364B1 (ja) | Ａｐｊ受容体のトリアゾールアゴニスト | |
| KR102007056B1 (ko) | 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸 | |
| JP5478488B2 (ja) | Ｊａｎｕｓキナーゼの阻害剤 | |
| JP7517992B2 (ja) | 化合物及びその使用 | |
| TWI725986B (zh) | 新穎苯氧甲基衍生物 | |
| JP6643545B2 (ja) | Ｔｒｐｍ８拮抗剤としてのアザスピロ誘導体 | |
| JP5759470B2 (ja) | オレキシン受容体調節因子としての二置換オクタヒドロピロロ［３，４−ｃ］ピロール | |
| AU2012356374B2 (en) | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors | |
| EA018721B1 (ru) | Модуляторы сигнального пути hedgehog | |
| JP2014517833A5 (enExample) | ||
| JP2017528519A5 (enExample) | ||
| EA018551B1 (ru) | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-KIT И PDGFR | |
| JP2014531465A5 (enExample) | ||
| AU2002365892A1 (en) | Metabotropic glutamate receptor-5 modulators | |
| JP2025515484A (ja) | Ｋｉｆ１８ａを阻害するための化合物 | |
| MX2011004779A (es) | Compuestos de arilo sustituido y su uso como inhibidores de hif. | |
| KR20120108963A (ko) | 스핑고신-1-포스페이트 수용체 효능제 | |
| JP2016520105A (ja) | 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 | |
| EP2809321A1 (en) | Phenyl -c-oxadiazole derivatives as inhibitors of leukotriene production combination therapy | |
| JPWO2021124172A5 (enExample) | ||
| JP2022513745A (ja) | アミノアジンアミド | |
| JPWO2019180646A5 (enExample) | ||
| RU2778641C2 (ru) | Производные конденсированной циклической мочевины в антагонист crhr2 |